Members of Rx&D join the International Structural Genomics Consortium
OTTAWA, Sept. 30, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to
complement an announcement made September 28 by members of the
International Structural Genomics Consortium (SGC) in London (UK).
"We applaud the international Structural Genomics Consortium (SGC) for
investing $48.9 million to further develop its open access research
program to support the discovery and development of new medicines.
"We congratulate today Eli Lilly Canada Inc. and Pfizer Canada Inc. for
joining the consortium. The other consortium funders comprise the
Canadian Institutes for Health Research, GlaxoSmithKline Inc., the
Novartis Research Foundation, the Ontario Ministry of Research and
Innovation, and the Wellcome Trust.
"Together, these organizations have committed over $48 million to the
consortium to sustain another four years of operation. Furthermore, the
four pharmaceutical company partners will provide more than $9 million
worth of in-kind contributions, primarily medicinal chemistry
resources, for collaborative discovery of chemical tool compounds that
target disease-linked proteins. The SGC will continue to operate from
its founder laboratories at the University of Oxford in the United
Kingdom and the University of Toronto in Ontario, Canada as well as
benefit from an extensive network of expert scientific collaborators
"Enhancing life sciences innovation in Canada depends upon a number of
important policy choices, including improving patient access to
innovative medicines and vaccines, and ensuring that Canada has a
competitive intellectual property regime to better compete with the
European Union, the United States and other leading nations.
"It is by working together that we can consolidate the position of
Canada as a leader in the provision of health care solutions to people
across the country and throughout the world."
Notes For Editors
The Structural Genomics Consortium was formed in 2004 and is a
registered UK charity (number 1097737) engaged in open access research
of relevance to the science of drug discovery. The Consortium is
supported by public and private sector funding. All of its findings are
made available to the global research community without restriction.
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: